Agora (API) Competitors

Agora (NASDAQ:API) and Enfusion (NYSE:ENFN) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.

Which has preferable valuation and earnings, API or ENFN?

Enfusion has higher revenue and earnings than Agora. Agora is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agora	$133.26M	2.24	-$87.22M	-$0.46	-7.04
Enfusion	$201.61M	6.94	$6.03M	$0.03	361.50

Does the MarketBeat Community favor API or ENFN?

Agora received 5 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 48.39% of users gave Agora an outperform vote while only 19.61% of users gave Enfusion an outperform vote.

Company	Underperform	Outperform
Agora	Outperform Votes 15 48.39%	Underperform Votes 16 51.61%
Enfusion	Outperform Votes 10 19.61%	Underperform Votes 41 80.39%

Which has more volatility & risk, API or ENFN?

Agora has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Does the media refer more to API or ENFN?

In the previous week, Agora and Agora both had 2 articles in the media. Agora's average media sentiment score of 1.69 beat Enfusion's score of 0.85 indicating that Agora is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agora	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Enfusion	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend API or ENFN?

Agora currently has a consensus target price of $6.00, indicating a potential upside of 85.19%. Enfusion has a consensus target price of $11.83, indicating a potential upside of 9.11%. Given Agora's stronger consensus rating and higher probable upside, research analysts clearly believe Agora is more favorable than Enfusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agora	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Enfusion	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is API or ENFN more profitable?

Enfusion has a net margin of 1.70% compared to Agora's net margin of -33.74%. Enfusion's return on equity of 6.67% beat Agora's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agora	-33.74%	-7.70%	-6.65%
Enfusion	1.70%	6.67%	4.86%

Do insiders & institutionals believe in API or ENFN?

40.4% of Agora shares are held by institutional investors. Comparatively, 81.1% of Enfusion shares are held by institutional investors. 14.6% of Agora shares are held by company insiders. Comparatively, 36.4% of Enfusion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Enfusion beats Agora on 12 of the 17 factors compared between the two stocks.